- Cassava Sciences (SAVA, Financial) announced the retirement of CMO Dr. James W. Kupiec, effective May 9, 2025.
- Dr. Jack Moore appointed as Senior VP of Clinical Development, effective April 28, 2025.
- The focus will be on simufilam for new indications including TSC-related epilepsy.
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, has announced a significant leadership change in its clinical development team. The company's Chief Medical Officer, Dr. James W. Kupiec, will retire on May 9, 2025, after successfully completing its Alzheimer's disease clinical trial program. His tenure was marked by a strong emphasis on patient care and maintaining dignity throughout the trial process.
In a strategic move, Cassava Sciences has appointed Dr. Jack Moore as the Senior Vice President of Clinical Development, with his term beginning on April 28, 2025. Dr. Moore will primarily focus on advancing the clinical evaluation of simufilam, an investigational oral treatment, for new potential indications such as tuberous sclerosis complex (TSC)-related epilepsy. His extensive experience in medical affairs and clinical development, particularly in central nervous system (CNS) disorders, will be instrumental in steering these initiatives.
Dr. Rick Barry, the CEO of Cassava Sciences, expressed gratitude for Dr. Kupiec's service and emphasized the importance of Dr. Moore's expertise in moving forward with the company's clinical programs. Dr. Moore brings a wealth of experience from leading pharmaceutical companies, which will aid in exploring additional potential applications for simufilam and identifying clinical collaborators.
This transition underscores Cassava Sciences' commitment to expanding therapeutic applications for CNS disorders, leveraging the company's investigational treatments for broader medical use.
